selegiline has been researched along with ergoline in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rinne, UK | 1 |
| Jenner, P; Marsden, CD | 1 |
| Adam, AM | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D | 1 |
| Bonuccelli, U; Del Dotto, P | 1 |
| Matsubara, K; Ohtaki, K; Shimizu, K; Shiono, H | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Csoka, AB; Shipko, S | 1 |
| Bosco, D; Bosco, F; Consoli, A; Plastino, M; Rotondo, A | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
5 review(s) available for selegiline and ergoline
| Article | Year |
|---|---|
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Clinical pharmacokinetics of cabergoline.
Topics: Age Factors; Antiparkinson Agents; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Ergolines; Female; Food-Drug Interactions; Humans; Kidney Diseases; Levodopa; Liver Diseases; Male; Selegiline; Sex Factors | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
2 trial(s) available for selegiline and ergoline
| Article | Year |
|---|---|
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Topics: Aged; Amphetamine; Amphetamines; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Methamphetamine; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1995 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
6 other study(ies) available for selegiline and ergoline
| Article | Year |
|---|---|
Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
Topics: Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Practical therapeutics: advances in the management of Parkinson's disease.
Topics: Ergolines; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.
Topics: 1-Methyl-4-phenylpyridinium; Analysis of Variance; Animals; Animals, Newborn; Azepines; Cabergoline; Caspases; Cell Count; Cycloheximide; Dizocilpine Maleate; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ergolines; Excitatory Amino Acid Antagonists; Herbicides; Immunohistochemistry; Mesencephalon; NADPH Dehydrogenase; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Organ Culture Techniques; Paraquat; Piperazines; Protein Synthesis Inhibitors; Quinoxalines; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2003 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonists; Dopamine Uptake Inhibitors; Ergolines; Female; Fluoxetine; Humans; Male; Monoamine Oxidase Inhibitors; Piperazines; Plants, Medicinal; Purines; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sleep Initiation and Maintenance Disorders; Sulfones; Testosterone; Time Factors; Treatment Outcome; Vasodilator Agents | 2006 |
Clozapine for medication-related pathological gambling in Parkinson disease.
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Clozapine; Ergolines; Female; Gambling; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline; Serotonin Antagonists | 2010 |